Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zonisamide

FDA-approved product (capsule, oral), marketed as Zonegran, Zonisade, Zonisamide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Zonisamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Focal-onset seizure
  • Partial epilepsy
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
FDA pharmacologic class
Anti-epileptic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli12.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis82.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Zonisamide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zonisamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Zonisamide Versus Topiramate in Migraine

    NCT06347497 · start 2024-04-01

    Registered record
    Registry ID
    NCT06347497
    Conditions
    Migraine
    Interventions
    Zonisamide 50 MG; Topiramate 50 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-04-01
    Completion
    2026-04-30
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionZonisamide 50 MG; Topiramate 50 MG
    PhasePhase 3
    Registry statusCompleted

  • The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

    NCT05134857 · start 2022-01-07

    Registered record
    Registry ID
    NCT05134857
    Conditions
    Alcohol Use Disorder (AUD)
    Interventions
    Zonisamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-01-07
    Completion
    2027-08-31
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder (AUD)
    InterventionZonisamide; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

    NCT04774250 · start 2021-11-10

    Registered record
    Registry ID
    NCT04774250
    Conditions
    Hearing Loss, Noise-Induced
    Interventions
    Zonisamide 100Mg Cap; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-11-10
    Completion
    2022-12-23
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHearing Loss, Noise-Induced
    InterventionZonisamide 100Mg Cap; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Noise-Induced Hearing Loss-Acute Exposure Treatment

    NCT04768569 · start 2021-10-04

    Registered record
    Registry ID
    NCT04768569
    Conditions
    Hearing Loss, Noise-Induced
    Interventions
    Zonisamide 100Mg Cap; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-10-04
    Completion
    2023-09-29
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHearing Loss, Noise-Induced
    InterventionZonisamide 100Mg Cap; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation

    NCT04939675 · start 2021-07-01

    Registered record
    Registry ID
    NCT04939675
    Conditions
    Epilepsy
    Interventions
    Zonisamide 100mg; Levetiracetam 500mg; LamoTRIgine 50mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-07-01
    Completion
    2025-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionZonisamide 100mg; Levetiracetam 500mg; LamoTRIgine 50mg
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy

    NCT03636958 · start 2021-02-15

    Registered record
    Registry ID
    NCT03636958
    Conditions
    Refractory Epilepsy
    Interventions
    Perampanel; conventional antiepileptic treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2021-02-15
    Completion
    2026-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Epilepsy
    InterventionPerampanel; conventional antiepileptic treatment
    PhaseNot applicable
    Registry statusWithdrawn

  • Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

    NCT04388319 · start 2020-05-27

    Registered record
    Registry ID
    NCT04388319
    Conditions
    Smoking Cessation
    Interventions
    Zonisamide; Bupropion; Halo G6 e-cigarette
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-05-27
    Completion
    2021-09-15
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation
    InterventionZonisamide; Bupropion; Halo G6 e-cigarette
    PhasePhase 3
    Registry statusCompleted

  • Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study

    NCT04182399 · start 2020-04-01

    Registered record
    Registry ID
    NCT04182399
    Conditions
    Parkinson Disease
    Interventions
    Zonisamide Capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2023-01-01
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionZonisamide Capsules
    PhaseNot applicable
    Registry statusCompleted

  • Zonisamide Outpatient Study

    NCT03376139 · start 2019-03-01

    Registered record
    Registry ID
    NCT03376139
    Conditions
    Post Traumatic Stress Disorder; Alcohol Use Disorder
    Interventions
    Zonisamide; Placebo Comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-03-01
    Completion
    2019-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder; Alcohol Use Disorder
    InterventionZonisamide; Placebo Comparator
    PhasePhase 2
    Registry statusWithdrawn

  • Prevention of Noise-induced Hearing Loss

    NCT02049073 · start 2017-10-31

    Registered record
    Registry ID
    NCT02049073
    Conditions
    Noise-induced Hearing Loss
    Interventions
    Zonisamide; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2017-10-31
    Completion
    2017-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNoise-induced Hearing Loss
    InterventionZonisamide; Methylprednisolone
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

    NCT02901041 · start 2017-09-21

    Registered record
    Registry ID
    NCT02901041
    Conditions
    Alcohol Dependence
    Interventions
    Zonisamide; Take Control; Placebo (for Zonisamide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-21
    Completion
    2022-01-04
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionZonisamide; Take Control; Placebo (for Zonisamide)
    PhasePhase 3
    Registry statusCompleted

  • Characterization of Epilepsy Patients BEEP 2b

    NCT02707965 · start 2017-06-08

    Registered record
    Registry ID
    NCT02707965
    Conditions
    Epilepsy
    Interventions
    Oxcarbazepine (brand name vs generic drugs); Divalproex Sodium (brand name vs generic drugs); Carbamazepine (brand name vs generic drugs); Lamotrigine (brand name vs generic drugs); levetiracetam (brand name vs generic drugs); Topiramate (brand name vs generic drugs); Zonisamide (brand name vs generic drugs); Phenytoin sodium (brand name vs generic drugs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-08
    Completion
    2018-09-04
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionOxcarbazepine (brand name vs generic drugs); Divalproex Sodium (brand name vs generic drugs); Carbamazepine (brand name vs generic drugs); Lamotrigine (brand name vs generic drugs) +4 more
    PhasePhase 1
    Registry statusCompleted

  • Effectiveness of Zonisamide in Alcohol Dependent Veterans

    NCT02368431 · start 2015-03-01

    Registered record
    Registry ID
    NCT02368431
    Conditions
    Alcohol Use Disorder
    Interventions
    Zonisamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-03-01
    Completion
    2018-10-01
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionZonisamide; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Ketogenic Diet in Infants With Epilepsy (KIWE)

    NCT02205931 · start 2015-01

    Registered record
    Registry ID
    NCT02205931
    Conditions
    Epilepsy
    Interventions
    Ketogenic diet; Antiepileptic drug therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2019-06
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionKetogenic diet; Antiepileptic drug therapy
    PhasePhase 4
    Registry statusUnknown

  • A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction

    NCT02220803 · start 2014-03

    Registered record
    Registry ID
    NCT02220803
    Conditions
    Obstructive Sleep Apnea; Sleep-Disordered Breathing; Blood Pressure; Hypertension
    Interventions
    Acetazolamide; nasal Continuous Positive Airway Pressure (nCPAP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2016-08
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea; Sleep-Disordered Breathing; Blood Pressure; Hypertension
    InterventionAcetazolamide; nasal Continuous Positive Airway Pressure (nCPAP)
    PhasePhase 2
    Registry statusCompleted